Analysis
Sirona Medical, a San Francisco-based radiology software company, has raised a $40 million Series D led by Avidity Partners, with participation from 8VC, GreatPoint Ventures, KLT Holdings and existing investors, according to The SaaS News. The round brings the company's total funding to approximately $150 million since it was founded in 2018 by Cameron Andrews.
## What Sirona actually sells Sirona describes its product as a unified 'radiology operating system' -- combining the PACS archive where medical images live, the diagnostic viewer radiologists use to read scans, structured reporting tools, and workflow AI, in a single cloud-native platform rather than a patchwork of separate vendor tools bolted together. That positioning puts it up against both legacy PACS incumbents that hospitals have run for decades and a newer wave of AI-native radiology startups, including names like Rad AI and Viz.ai, that have raised their own rounds targeting specific pieces of the reading workflow.
“The company isn't disclosing revenue or customer counts alongside this raise, and the announcement doesn't include a valuation.”
The company isn't disclosing revenue or customer counts alongside this raise, and the announcement doesn't include a valuation. What it does show is a steady late-stage pattern: a Series D after prior rounds that collectively pushed cumulative funding to roughly $150 million, in a sector where hospital procurement cycles are notoriously slow and where AI vendors increasingly need enterprise-grade reliability, not just a strong demo, to win multi-year contracts.
The broader context is a persistent shortage of radiologists relative to imaging volume, which has made 'AI-assisted triage and reporting' one of the few health-IT categories where hospital systems are still opening new budget lines even as broader healthcare IT spending stays cautious. Worth noting: software that touches diagnostic reporting directly also carries more regulatory and liability exposure than a pure scheduling or billing tool, which is part of why platforms like Sirona's tend to raise in large, infrequent rounds rather than a rapid cadence of smaller ones -- the sales and compliance cycle is long by design.